🇺🇸 FDA
Patent

US 12257311

Multimeric T-cell modulatory polypeptides and methods of use thereof

granted A61KA61K2039/605A61K2039/6056

Quick answer

US patent 12257311 (Multimeric T-cell modulatory polypeptides and methods of use thereof) held by Cue Biopharma, Inc. expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cue Biopharma, Inc.
Grant date
Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61K, A61K2039/605, A61K2039/6056, A61K39/001114, A61K39/001153